Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Janssen (J&J Innovative Medicine)

Status

Conditions: Relapsed or Refractory Multiple Myeloma

Treatments: Drug: Talquetamab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05503550

CR109169

64407564MMY4002 (Other Identifier)

Details and patient eligibility

About

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Sex

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria